Xbrane Biopharma kliver in på First North - Affärsvärlden

MFN.se > Xbrane Biopharma > Xbrane Biopharma releases

Xbrane has world leading expertise in developing generics for long-acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the SEK 106 billions ophthalmic VEGFa inhibitor market. Xlucane is in phase III and filing of marketing authorization application is planned for Q3 2021. Xbrane has additionally three biosimilars in its pipeline targeting SEK 100 billions in originator sales. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market.

Xbrane Biopharma is advancing its portfolio of biosimilars with targeted launch of leading product Xlucane (Lucentis biosimilar) in 2022.

Xbrane utser Anette Lindqvist till ny Chief Financial Officer

We view the increasing focus on other pipeline candidates as an important step. We see Xdivane and Xcimzane as particularly interesting assets and expect the advancements of these to be key long-term value drivers for Xbrane, offering significant upside to our base case with Xlucane.

Xbrane Biopharma publicerar bokslutskommuniké för 2020

Xbrane further states that it will initially fund the development of its biosimilar pipeline using resources freed up from Xlucane development, but notes that long-term successful development will require it to raise sufficient capital in the market. Xbrane’s specific advantage is that its bacterial fermentation system is highly efficient, (up to eightfold higher yields claimed), at producing smaller, biological drugs such as antibody fragments like Xlucane (the lead product) or certolizumab (a pipeline project), or simple enzymes such as pegaspargase (a pipeline project). With plans to obtain EU and US marketing authorizations for its Xlucane ranibizumab biosimilar, Xbrane has renegotiated a pre-existing intellectual property licensing agreement with Vaxiion Therapeutics, including the payment of royalties through February 2024. US Biosimilars See A Banner Year Despite Few Approvals The market pipeline charts show products that have not received FDA approval and are expected to launch in one to four years. These charts suggest a bright future for biosimilars, as they document a large number of existing and new suppliers investing in biosimilars. The pipeline charts also capture the View Wet AMD Pipeline View Dry AMD Pipeline “Keeping an eye on drug development in AMD is difficult.

Xbranes huvudkontor ligger i Solna strax utanför Stockholm. Xbrane är noterat på Nasdaq Stockholm under kortnamnet XBRANE.
Medicinska termer på engelska

Xbrane har ytterligare fyra biosimilarer i sin pipeline som adresserar en marknad om 8,7 miljarder EUR i originalprodukternas försäljning. Xbranes huvudkontor ligger i Solna strax utanför Stockholm. Xbrane är noterat på Nasdaq Stockholm under kortnamnet XBRANE. För mer information besök www.xbrane.com. Xbrane’s core pipeline, with the lead asset and Lucentis biosimilar Xlucane, is focused on the so called third wave of biosimilars, that is versions of the more complex mAbs or antibody fragment multi-billion blockbuster drugs coming off patent after Xbrane har ytterligare fyra biosimilarer i sin pipeline som adresserar en marknad om 8,7 miljarder EUR i originalprodukternas försäljning. Xbranes huvudkontor ligger i Solna strax utanför Stockholm.

At present, Xbrane Biopharma is an R&D-driven company with around 40 employees and four biosimilars in Xbrane Biopharma AB (publ) Main office Telefon: +46 (0) 76 034 67 33 Email: info@xbrane.com Adress: Xbrane Biopharma Retzius väg 8 171 65 Solna Sweden “Talar för Xbrane gör också att bolaget, till skillnad från en del andra forskningsbolag, inte är en one trick pony. Även om Xlucane-projektet av någon anledning skulle fallera, bli försenat eller dylikt, så har bolaget en pipeline med andra biosimilarprojekt samt inte minst – bolagets teknologiplattform. The deal will contribute significant funding and expertise for the development and commercialization of Xlucane and will help to accelerate the development of our pipeline of biosimilars as well as the transformation of Xbrane into a major player in the fast-growing global biosimilars market,” said Anders Tullgren, Chairman of the Board of Directors at Xbrane. Xbrane har ytterligare tre biosimilarer i sin pipeline som adresserar en marknad om 100 miljarder SEK i originalprodukternas försäljning. Xbranes huvudkontor ligger i Solna strax utanför Stockholm. Xbrane är noterat på Nasdaq Stockholm under kortnamnet XBRANE. För mer information besök www.xbrane.com.
När ska bilskatt betalas

För mer information besök www.xbrane.com. Xbrane har ytterligare fyra biosimilarer i sin pipeline som adresserar en marknad om 8,7 miljarder EUR i originalprodukternas försäljning. Xbranes huvudkontor ligger i Solna strax utanför Stockholm. Xbrane är noterat på Nasdaq Stockholm under kortnamnet XBRANE. För mer information besök www.xbrane.com.

Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane provides an exceptionally attractive exposure to the rapidly growing biosimilars market without the significant clinical and approval risk that is often present in biotech companies. We maintain the Outperform rating and raise the target price to SEK 155 per share, corresponding to an equity value of SEK 3 billion non-diluted, derived from a project-based, risk-adjusted DCF valuation of Xbrane Biopharma announces that Margareta Hagman will take on the position as interim CFO from September 30, 2020 until a new CFO is in place. Hagman will be part of the management team during the time as interim CFO. She has an extensive experience as CFO from BioGaia AB and holds board positions in two listed companies. This potentially allows Xbrane to run a broader pipeline in future as it only needs to manufacture the product and run clinical equivalence trials to gain regulatory approval.
Iagg stock price

Head of CMC Regulatory Affairs within Biologics , Xbrane

Även om Xlucane-projektet av någon anledning skulle fallera, bli försenat eller dylikt, så har bolaget en pipeline med andra biosimilarprojekt samt inte minst – bolagets teknologiplattform. Xbrane Biopharma AB (publ) Main office Telefon: +46 (0) 76 034 67 33 Email: info@xbrane.com Adress: Xbrane Biopharma Retzius väg 8 171 65 Solna Sweden Spara & Investera Aktier Aktieinspiration Aktiegeneratorn Xbrane har ytterligare tre biosimilarer i sin pipeline som adresserar en marknad om 100 miljarder SEK i originalprodukternas försäljning. Xbranes huvudkontor ligger i Solna strax utanför Stockholm. Xbrane är noterat på Nasdaq Stockholm under kortnamnet XBRANE. För mer information besök www.xbrane.com. Xbrane har ytterligare fyra biosimilarer i sin pipeline som adresserar en marknad om 8,7 miljarder EUR i originalprodukternas försäljning. Xbranes huvudkontor ligger i Solna strax utanför Stockholm.

Brandkonsult borås

Head of CMC Regulatory Affairs within Biologics , Xbrane

Xbrane's core pipeline, with the lead asset and Lucentis biosimilar Xlucane, is focused on the so called third wave of biosimilars, that is versions Xbrane Biopharma, ett bolag som har legat dött och bortglömt i över 1,5 år, Med hela dagens pipeline inräknad så är Xbranes adresserbara The company's pipeline consists of a wide range of development candidates originated from Xbrane's patented high-yield platform technology. Xbrane Biopharma AB invites to a teleconference for investors, analysts and biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane Biopharma AB's annual report for 2020 is now available at the Xbrane has additionally three biosimilars in its pipeline targeting SEK Tillsammans med Bausch + Lomb och STADA bedömer vi att Xbrane är väl Stark pipeline med fortsatt intresse från STADA. Xbrane startade Köp aktier i Xbrane Biopharma - enkelt och billigt hos Avanza Bank.